Inhibikase Therapeutics (IKT) News Today $3.28 +0.55 (+20.15%) (As of 12/6/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Trading 7% Higher - Time to Buy?November 30, 2024 | marketbeat.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comInhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityNovember 14, 2024 | globenewswire.comJefferies Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy RecommendationNovember 9, 2024 | msn.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Financial Moves and Promising Pipeline Fuel Buy RatingOctober 24, 2024 | markets.businessinsider.comInhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Acquires 145,000 SharesOctober 24, 2024 | insidertrades.comPerceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics IncOctober 22, 2024 | finance.yahoo.comInhibikase Therapeutics Secures Funding and Strengthens LeadershipOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics closes up to $275M financing, advances IkT-001ProOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial HypertensionOctober 21, 2024 | globenewswire.comInhibikase Therapeutics Secures $110M for Drug DevelopmentOctober 12, 2024 | finance.yahoo.comSteven Cohen's Strategic Acquisition of Inhibikase Therapeutics SharesOctober 12, 2024 | finance.yahoo.comInhibikase Therapeutics Unveils PAH and Parkinson’s Drug PipelineOctober 10, 2024 | finance.yahoo.comWhy Inhibikase Therapeutics (IKT) Stock Is Up 50% TodayOctober 10, 2024 | benzinga.comInhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial HypertensionOctober 9, 2024 | globenewswire.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024August 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityAugust 14, 2024 | globenewswire.comWhat Wall Street expects from Inhibikase Therapeutics's earningsAugust 14, 2024 | markets.businessinsider.comInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024August 7, 2024 | globenewswire.comInhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's DiseaseJune 17, 2024 | globenewswire.comInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsJune 5, 2024 | globenewswire.comInhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)May 21, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionMay 20, 2024 | globenewswire.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 19, 2024 | msn.comEarnings call: Inhibikase Therapeutics reports on drug trials progressMay 18, 2024 | investing.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 16, 2024 | msn.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionMay 9, 2024 | globenewswire.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 22, 2024 | msn.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 20, 2024 | investing.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 18, 2024 | globenewswire.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | markets.businessinsider.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionApril 3, 2024 | globenewswire.comBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory ProgressApril 3, 2024 | markets.businessinsider.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsApril 2, 2024 | finance.yahoo.comQ4 2023 Inhibikase Therapeutics Inc Earnings CallMarch 29, 2024 | finance.yahoo.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 27, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.com Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent warning about AI (Ad)My research shows we're facing the biggest threat to our existence in the history of our Republic … It's not who's in the White House … And it's not any kind of war, either. It's Artificial Intelligence … Click here to learn more. IKT Media Mentions By Week IKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.000.72▲Average Medical News Sentiment IKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼11▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TECX News TRML News TSHA News GLUE News EXAI News SANA News PROK News HUMA News ALLO News MGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 12/6/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredUrgent warning about your moneyThe stock market is booming … And Bitcoin just hiked through the roof. But don't get fooled by the "good...Weiss Ratings | SponsoredElon declares war on company he co-founded!?Elon Musk is leading humanity into the new era of AI. He’s just received a fresh $6 billion in funding for ...Porter & Company | SponsoredWall Street genius says this bubble has run its course – what to doWhile the media is telling you to be excited about the stock market, Wall Street and the market's top experts ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts